Multiple Sclerosis

Medical Clinics of North America

Volumn 93, Issue 2, 2009, Pages 451-476

  Courtney, Ardith M ^a   Treadaway, Katherine ^a   Remington, Gina ^a   Frohman, Elliot ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Disease modifying therapy; Magnetic resonance imaging; Multiple sclerosis; Optic neuritis

Indexed keywords

AZATHIOPRINE; BETA1A INTERFERON; CYCLOPHOSPHAMIDE; DEXAMETHASONE; GLATIRAMER; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; INTERFERON; INTERFERON BETA SERINE; METHOTREXATE; METHYLPREDNISOLONE SODIUM SUCCINATE; MITOXANTRONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NAPROXEN; NATALIZUMAB; PREDNISONE;

ACUTE LEUKEMIA; ALOPECIA; AMENORRHEA; AMINOTRANSFERASE BLOOD LEVEL; ANAPHYLAXIS; ANEMIA; ASEPTIC MENINGITIS; BLADDER DYSFUNCTION; BONE MARROW SUPPRESSION; CARDIOTOXICITY; CEREBROSPINAL FLUID ANALYSIS; DIAGNOSTIC IMAGING; DIARRHEA; DIPLOPIA; DISEASE CLASSIFICATION; DRUG DOSE TITRATION; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; ENTEROPATHY; ENVIRONMENTAL FACTOR; FATIGUE; GAIT DISORDER; GASTROINTESTINAL SYMPTOM; HAIR LOSS; HEMORRHAGIC CYSTITIS; HEREDITY; HERPES ZOSTER; HUMAN; HYPERCOAGULABILITY; IMMUNOMODULATION; INFERTILITY; INJECTION SITE REACTION; INTERNUCLEAR OPHTHALMOPLEGIA; INTERSTITIAL PNEUMONIA; LEUKEMIA; LIVER CIRRHOSIS; LIVER TOXICITY; LYMPHOCYTOPENIA; LYMPHOMA; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE SCLEROSIS; NAUSEA; NEOPLASM; NEPHROTOXICITY; NEUROPATHOLOGY; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NEURITIS; PANCREATITIS; PREVALENCE; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PROMYELOCYTIC LEUKEMIA; RECURRENT DISEASE; REMISSION; REVIEW; SEXUAL DYSFUNCTION; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT DURATION; URINARY TRACT INFECTION; VIRUS HEPATITIS; VOMITING;

ANTI-INFLAMMATORY AGENTS; BRAIN; EVIDENCE-BASED MEDICINE; HUMANS; IMMUNOLOGIC FACTORS; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS;

EID: 61449231715     PISSN: 00257125     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mcna.2008.09.014     Document Type: Review

References (72)

1. Anderson D.W., et al. Revised estimate of the prevalence of multiple sclerosis in the United States. Ann Neurol 31 3 (1992) 333-336
2. Weinshenker B.G., et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 112 Pt 1 (1989) 133-146
3. Hayes C.E., and Donald Acheson E. A unifying multiple sclerosis etiology linking virus infection, sunlight, and vitamin D, through viral interleukin-10. Med Hypotheses 71 1 (2008) 85-90
4. Kampman M.T., and Brustad M. Vitamin D: a candidate for the environmental effect in multiple sclerosis. Observations from Norway. Neuroepidemiology 30 3 (2008) 140-146
5. Brex P.A., et al. Assessing the risk of early multiple sclerosis in patients with clinically isolated syndromes: the role of a follow up MRI. J Neurol Neurosurg Psychiatry 70 3 (2001) 390-393
6. Abramsky O., et al. Suppressive effect of pregnancy on MS and EAE. Prog Clin Biol Res 146 (1984) 399-406
7. Devonshire V., et al. The immune system and hormones: review and relevance to pregnancy and contraception in women with MS. Int MS J 10 2 (2003) 44-50
8. Starnawski M., et al. [Pregnancy in women with multiple sclerosis (MS): a report of 2 cases]. Ginekol Pol 69 12 (1998) 1032-1034
9. Runmarker B., and Andersen O. Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up. Brain 116 Pt 1 (1993) 117-134
10. Kappos L., et al. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet 370 9585 (2007) 389-397
11. Lublin F.D., and Reingold S.C. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 46 4 (1996) 907-911
12. McDonald W.I., et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol 50 1 (2001) 121-127
13. Poser C.M., et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 13 3 (1983) 227-231
14. Beck R.W., et al. The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis: the Optic Neuritis Study Group. N Engl J Med 329 24 (1993) 1764-1769
15. Comi G., et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 357 9268 (2001) 1576-1582
16. Freedman M.S., et al. Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: a consensus statement. Arch Neurol 62 6 (2005) 865-870
17. Martinelli V., et al. Paraclinical tests in acute-onset optic neuritis: basal data and results of a short follow-up. Acta Neurol Scand 84 3 (1991) 231-236
18. Noseworthy J.H., et al. Multiple sclerosis. N Engl J Med 343 13 (2000) 938-952
19. Frohman E.M., Racke M.K., and Raine C.S. Multiple sclerosis: the plaque and its pathogenesis. N Engl J Med 354 9 (2006) 942-955
20. Cannella B., and Raine C.S. The adhesion molecule and cytokine profile of multiple sclerosis lesions. Ann Neurol 37 4 (1995) 424-435
21. Hauser S.L., et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 358 7 (2008) 676-688
22. Lucchinetti C.F., et al. Distinct patterns of multiple sclerosis pathology indicates heterogeneity on pathogenesis. Brain Pathol 6 3 (1996) 259-274
23. Guy J., et al. Enhancement and demyelination of the intraorbital optic nerve: fat suppression magnetic resonance imaging. Ophthalmology 99 5 (1992) 713-719
24. Optic Neuritis Study Group. The 5-year risk of MS after optic neuritis: experience of the optic neuritis treatment trial. Neurology 49 5 (1997) 1404-1413
25. Jacobs L., Kinkel P.R., and Kinkel W.R. Silent brain lesions in patients with isolated idiopathic optic neuritis: a clinical and nuclear magnetic resonance imaging study. Arch Neurol 43 5 (1986) 452-455
26. PRISMS-4: long-term efficacy of interferon-beta-1a in relapsing MS. Neurology 56 12 (2001) 1628-1636
27. Jacobs L.D., et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 343 13 (2000) 898-904
28. Jacobs L.D., et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis: the Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 39 3 (1996) 285-294
29. Beiske A.G., and Myhr K.M. Lipoatrophy: a non-reversible complication of subcutaneous interferon-beta 1a treatment of multiple sclerosis. J Neurol 253 3 (2006) 377-378
30. O'Sullivan S.S., et al. Panniculitis and lipoatrophy after subcutaneous injection of interferon beta-1b in a patient with multiple sclerosis. J Neurol Neurosurg Psychiatry 77 12 (2006) 1382-1383
31. Frohman E.M., et al. Disease modifying agent related skin reactions in multiple sclerosis: prevention, assessment, and management. Mult Scler 10 3 (2004) 302-307
32. Guthrie T.C., and Nelson D.A. Influence of temperature changes on multiple sclerosis: critical review of mechanisms and research potential. J Neurol Sci 129 1 (1995) 1-8
33. Humm A.M., et al. Quantification of Uhthoff's phenomenon in multiple sclerosis: a magnetic stimulation study. Clin Neurophysiol 115 11 (2004) 2493-2501
34. Smith K.J., and McDonald W.I. The pathophysiology of multiple sclerosis: the mechanisms underlying the production of symptoms and the natural history of the disease. Philos Trans R Soc Lond B Biol Sci 354 1390 (1999) 1649-1673
35. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 45 7 (1995) 1277-1285
36. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 352 9139 (1998) 1498-1504
37. Karandikar N.J., et al. Glatiramer acetate (Copaxone) therapy induces CD8(+) T cell responses in patients with multiple sclerosis. J Clin Invest 109 5 (2002) 641-649
38. Calabresi P.A., et al. The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology 69 14 (2007) 1391-1403
39. Kleinschmidt-DeMasters B.K., and Tyler K.L. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 353 4 (2005) 369-374
40. Stuve O., et al. Potential risk of progressive multifocal leukoencephalopathy with natalizumab therapy: possible interventions. Arch Neurol 64 2 (2007) 169-176
41. Goodin D.S., et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 58 2 (2002) 169-178
42. Ramkumar B., et al. Acute promyelocytic leukemia after mitoxantrone therapy for multiple sclerosis. Cancer Genet Cytogenet 182 2 (2008) 126-129
43. Boster A., et al. Intense immunosuppression in patients with rapidly worsening multiple sclerosis: treatment guidelines for the clinician. Lancet Neurol 7 2 (2008) 173-183
44. Costello F., et al. Combination therapies for multiple sclerosis: scientific rationale, clinical trials, and clinical practice. Curr Opin Neurol 20 3 (2007) 281-285
45. Frohman E.M., et al. Therapeutic considerations for disease progression in multiple sclerosis: evidence, experience, and future expectations. Arch Neurol 62 10 (2005) 1519-1530
46. Zivadinov R., et al. Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS. Neurology 57 7 (2001) 1239-1247
47. Frohman E.M., et al. Corticosteroids for multiple sclerosis: I. Application for treating exacerbations. Neurotherapeutics 4 4 (2007) 618-626
48. Shah A., et al. Corticosteroids for multiple sclerosis: II. Application for disease-modifying effects. Neurotherapeutics 4 4 (2007) 627-632
49. Chrousos G.A., et al. Side effects of glucocorticoid treatment: experience of the Optic Neuritis Treatment Trial. JAMA 269 16 (1993) 2110-2112
50. Johnson K.P., et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 45 7 (1995) 1268-1276
51. Rudick R.A., et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 354 9 (2006) 911-923
52. Strasser-Fuchs S., et al. Clinically benign multiple sclerosis despite large T2 lesion load: can we explain this paradox?. Mult Scler 14 2 (2008) 205-211
53. Thompson A.J., et al. Patterns of disease activity in multiple sclerosis. BMJ 301 6742 (1990) 44-45
54. Miller D.H., et al. The role of magnetic resonance techniques in understanding and managing multiple sclerosis. Brain 121 Pt 1 (1998) 3-24
55. Khan O.A., and Dhib-Jalbut S.S. Neutralizing antibodies to interferon beta-1a and interferon beta-1b in MS patients are cross-reactive. Neurology 51 6 (1998) 1698-1702
56. Rudick R.A., et al. Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG). Neurology 50 5 (1998) 1266-1272
57. Runkel L., et al. Structural and functional differences between glycosylated and non-glycosylated forms of human interferon-beta (IFN-beta). Pharm Res 15 4 (1998) 641-649
58. European Study Group on interferon beta-1b in secondary progressive MS. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet 352 9139 (1998) 1491-1497
59. Giovannelli M., et al. Early physiotherapy after injection of botulinum toxin increases the beneficial effects on spasticity in patients with multiple sclerosis. Clin Rehabil 21 4 (2007) 331-337
60. Ward A.B. Spasticity treatment with botulinum toxins. J Neural Transm 115 4 (2008) 607-616
61. Goodman A.D., et al. Fampridine-SR in multiple sclerosis: a randomized, double-blind, placebo-controlled, dose-ranging study. Mult Scler 13 3 (2007) 357-368
62. Hayes K.C. Fampridine-SR for multiple sclerosis and spinal cord injury. Expert Rev Neurother 7 5 (2007) 453-461
63. Romani A., et al. Fatigue in multiple sclerosis: multidimensional assessment and response to symptomatic treatment. Mult Scler 10 4 (2004) 462-468
64. Peterson E.W., et al. Injurious falls among middle aged and older adults with multiple sclerosis. Arch Phys Med Rehabil 89 6 (2008) 1031-1037
65. Debouverie M., et al. Physical dimension of fatigue correlated with disability change over time in patients with multiple sclerosis. J Neurol 255 5 (2008) 633-636
66. Lebrun C., et al. Levocarnitine administration in multiple sclerosis patients with immunosuppressive therapy-induced fatigue. Mult Scler 12 3 (2006) 321-324
67. Justus N., et al. [Treatment with botulinum toxin in neurologic pediatrics]. Kinderkrankenschwester 26 7 (2007) 274-276
68. Smith C.P., Somogyi G.T., and Boone T.B. Botulinum toxin in urology: evaluation using an evidence-based medicine approach. Nat Clin Pract Urol 1 1 (2004) 31-37
69. Thompson A.J., et al. Clinical management of spasticity. J Neurol Neurosurg Psychiatry 76 4 (2005) 459-463
70. Litwiller S.E., Frohman E.M., and Zimmern P.E. Multiple sclerosis and the urologist. J Urol 161 3 (1999) 743-757
71. Rudick R.A., et al. Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis: the Multiple Sclerosis Collaborative Research Group (MSCRG). Neurology 49 2 (1997) 358-363
72. Tintore M. Rationale for early intervention with immunomodulatory treatments. J Neurol 255 Suppl 1 (2008) 37-43